

1 **Bimodal distributions of anti-*Trypanosoma cruzi***  
2 **antibody levels in blood donors are associated**  
3 **with parasite detection and antibody waning in**  
4 **peripheral blood.**

5

6 Mirta C. Remesar <sup>1</sup> ¶, Ester C. Sabino <sup>2,3</sup> ¶, Lewis F. Buss<sup>4</sup> ¶, Claudio D. Merlo <sup>5</sup> & ,

7 Mónica G. López <sup>5</sup> & , Sebastián L. Humeres <sup>6</sup> & , Pavón A. Héctor <sup>5</sup> & , Clara Di

8 Germanio C. <sup>7</sup> & , Sonia Bakkour Coco <sup>7</sup> & , Léa C. Oliveira-da Silva <sup>2</sup> & , Marcelo

9 Martins Pinto Filho <sup>8</sup> & , Antonio Luiz P. Ribeiro <sup>8</sup> & , Michael P. Busch <sup>7,9</sup> ¶, Ana E. del

10 Pozo <sup>1,10</sup> ¶

11

12 <sup>1</sup> Centro Regional de Hemoterapia Garrahan, Hospital de Pediatría Prof. Dr. J. P.

13 Garrahan, Ciudad de Buenos Aires, Buenos Aires, Argentina

14

15 <sup>2</sup> Laboratório de Parasitologia Medica (LIM-46), Hospital das Clínicas da

16 Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil

17

18 <sup>3</sup> Departamento de Moléstias Infecciosas e Parasitárias, Hospital das Clínicas da  
19 Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo,  
20 Brazil.

21

22 <sup>4</sup> Centre for Academic Primary care, University of Bristol, Bristol, United Kingdom

23 <sup>5</sup> Centro Especializado en Hemoterapia, Resistencia, Chaco, Argentina

24

25 <sup>6</sup> Facultad de Ciencias Exactas y Agrimensura, Universidad Nacional del Nordeste,  
26 Ciudad de Corrientes, Corrientes, Argentina

27

28 <sup>7</sup> Vitalant Research Institute, San Francisco, California, United States of America

29

30 <sup>8</sup> Telehealth Center and Cardiology Service, Hospital das Clínicas, Universidade  
31 Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

32

33 <sup>9</sup> Department of Laboratory Medicine, University of California, San Francisco, San  
34 Francisco, California, United States of America

35

36 <sup>10</sup> Chaco Province Blood Program Consultant, Ministerio de Salud de la Provincia  
37 de Chaco, Resistencia, Chaco, Argentina

38

39

40 \* Corresponding author

41 E-mail: [mirtaremesar@gmail.com](mailto:mirtaremesar@gmail.com) (MR)

42 \* Corresponding author

43 E-mail: [sabinoec@gmail.com](mailto:sabinoec@gmail.com) (SE)

44

45 ¶ These authors contributed equally to this work

46 & These authors also contributed equally to this work

## 47 **Abstract**

## 48 **Background**

49 In our previous study of blood donors in the Argentinian Chaco Province, we  
50 documented bimodal distributions of anti-*Trypanosoma cruzi* antibody (Ab) levels,  
51 suggesting potential self-cure in donors with low-reactive samples. This study  
52 aimed to correlate “high” and “low” Ab level groups, defined by a mathematical  
53 model, with parasitemia and electrocardiogram findings. Ab decline over time was  
54 also assessed.

## 55 **Methodology / Principal Findings**

56 We invited *T. cruzi* Ab reactive blood donors to enroll in the study from October  
57 2018 to November 2019 with a follow up visit two years later. Blood samples were  
58 tested for *T. cruzi* Ab by: Chagatest ELISA Lisado and Chagatest ELISA  
59 Recombinante v.4.0 (Wiener Lab, Argentina); VITROS Immunodiagnostic Products  
60 Anti-T.cruzi (Chagas) (Ortho-Clinical Diagnostics Inc., UK), and Architect Chagas  
61 (Abbott Laboratories, Germany). Target capture PCR was performed on lysed  
62 whole blood samples from enrollment visits and electrocardiograms on second  
63 visits.  
64 Four hundred fifty donors were recruited, but 68 were excluded due to negative  
65 results on all study Ab assays. Ab level distributions were bimodal and classified as  
66 “high” or “low” at a calculated threshold for each of four assays. There were 160  
67 donors with low and 179 with high Ab results on all assays. The remainder 43 were  
68 discordant reactive. Ninety-seven percentage of the PCR positive donors were  
69 among the concordant high Ab group. During the 2-4 year follow-up interval,  
70 relative Ab declines by three assays were significantly greater among those  
71 classified as low Ab and with negative PCR results.

## 72 **Conclusions / Significance**

73 Ab reactivity is associated with PCR-detectable parasitemia. Greater Ab declines  
74 were detected among donors with low and/or discordant Ab reactivity and negative  
75 PCR results, suggesting spontaneous parasite clearance in these donors.

76

## 77 **Introduction**

78 Chagas disease (CD), caused by the *Trypanosoma cruzi* (*T. cruzi*) parasite, is a  
79 significant public health concern affecting approximately 6 million people worldwide  
80 [1]. Recognized as a neglected tropical disease, CD is primarily transmitted  
81 through contact with the feces of infected triatomine bugs [1]. Approximately 70  
82 million people reside in areas at risk of exposure to this vector and parasite [2].  
83 The diagnosis of chronically infected individuals relies on antibody (Ab) detection,  
84 as parasitemia is typically low and intermittent [1]. Due to well documented risks of  
85 transfusion transmission of *T. cruzi*, all blood donations are screened for *T. cruzi*  
86 Ab in endemic countries in Latin America, while donations from first time donors or  
87 travelers to endemic countries are screened for *T. cruzi* Ab in many non-endemic  
88 countries [3]. However, nearly one-third of individuals including blood donors  
89 identified as seropositive exhibit low Ab levels or discordant test results [4]. These  
90 borderline or low level Ab cases share risk factors with unequivocal seropositive  
91 cases, strongly suggesting true exposure to *T. cruzi* rather than false-positive  
92 results [5,6]. Since *T. cruzi* infection is widely considered to be lifelong [7], these  
93 low reactive samples are often considered as indicative of active infection and  
94 these patients and donors are deferred and counseled as infected and may be  
95 treated. This underscores the need to enhance the sensitivity of existing tests and  
96 forms the basis for PAHO's recommendation of parallel screening using two  
97 different immunoassays for CD diagnosis [8].

98 Our previous study conducted in the highly endemic Chaco province of Argentina  
99 revealed a bimodal distribution of Ab signals in seroreactive blood donors when  
100 tested in parallel with six different immunoassays [6,9]. The bimodal distribution

101 led us to hypothesize the existence of two infection outcome phenotypes, with low-  
102 level Ab cases reflecting spontaneously resolved and high-level Ab reflecting  
103 chronic/active *T. cruzi* infections. We further hypothesized that parasite clearance  
104 would diminish the antigenic stimulus, resulting in gradual seroreversion on follow-  
105 up testing. Consistent with our hypotheses, spontaneous cure has also been  
106 observed in other studies [10-15]

107 In the current study, we enrolled Chagas Ab-reactive donors at the same blood  
108 bank in the Chaco region as our previous study and conducted baseline and  
109 follow-up visits to confirm the bimodal distribution and correlate Ab levels with PCR  
110 results. Additionally, the follow-up visits allowed us to assess Ab decline over time  
111 and disease penetrance as measured by electrocardiogram (ECG).

## 112 **Methods**

### 113 **Study design**

114 In Argentina, blood donor screening policies mandate performance of two *T. cruzi*  
115 Ab tests based on different assay designs, such as parasite lysate and  
116 recombinant antigens. This prospective cohort study involved seropositive blood  
117 donors with at least one reactive screening test for *T. cruzi* at the Servicio  
118 Especializado en Hemoterapia in Chaco Province, Argentina, from 2009 to 2018.  
119 Eligible Ab-reactive donors were identified using blood bank records, and basic  
120 demographic data were retrieved. We organized the work within the province to  
121 secure local collaboration, ensuring an efficient process of recruitment, consent,  
122 sample acquisition and processing, and ECG testing. A local telemarketer was

123 trained to make calls to donors in accordance with a protocol established with the  
124 local health providers.

125 The initial enrollment appointments and visits were conducted from October 2018  
126 to November 2019. Donors completed a questionnaire regarding their risk factors  
127 for exposure to CD, and blood samples were collected for serological tests and  
128 PCR. Donors who reported previous treatment for CD were excluded from the  
129 study. The second follow-up visits took place from November 2021 to March 2023.  
130 During these visits, a second blood sample was collected for Ab testing, and each  
131 participant underwent an ECG.

132

### 133 **Serology testing**

134 Four commercial tests were used for the characterization of *T. cruzi* Abs in the  
135 samples: Chagatest ELISA Lisado (Wiener Lab, Rosario, Argentina), Chagatest  
136 ELISA Recombinante v.4.0 (Wiener Lab, Rosario, Argentina), VITROS  
137 Immunodiagnostic Products Anti-T.cruzi (Chagas) (Ortho-Clinical Diagnostics Inc.,  
138 Pencoed, Bridgend, UK), and Architect Chagas (Abbott Laboratories, Wiesbaden,  
139 Germany). The Chaco Province blood bank performed the Wiener and Abbott  
140 assays, and Vitalant Research Institute (San Francisco CA) was responsible for  
141 the Ortho assay. All *T. cruzi* Ab testing was performed according to the  
142 manufacturer's instructions.

143

### 144 **Polymerase Chain Reaction (PCR)**

145 During the enrolment appointment, 20 mL of EDTA-anticoagulated whole blood  
146 was drawn from each donor and mixed with an equal volume of guanidine (6 M)/  
147 EDTA (200 mM) solution. Aliquots were prepared and stored at -20 degrees C until  
148 they were shipped to Vitalant Research Institute (San Francisco, CA) for PCR  
149 testing. Aliquots of lysed whole blood samples were tested using a target-capture  
150 (TC) real-time (RT) PCR assay, as previously described [12]. Capture of *T. cruzi*  
151 DNA was performed using magnetic beads coated with three 20-mer capture  
152 oligonucleotides:

153 TCZ 1 CGAGCTCTTGCCCACACGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;

154 TCZ 2

155 CCTCCAAGCAGCGGATAGTTCAGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA and;

156 TCZ 3 TGCTGCASTCGGCTGATCGTTTTTC-GAAAAAAAAAAAAAAAAAAAAA

157 AAAAAA.

158 The captured DNA targets were eluted from the magnetic beads and real-time  
159 PCR amplified on an Applied Biosystems 7500 thermocycler. Briefly, 25 µL of DNA  
160 was added to 50 µL of PCR reaction mix. The PCR conditions were 10 min at 95°  
161 C, followed by 45 cycles of 30 sec at 95° C, 30 sec at 64° C, and 45 sec at 72° C.  
162 After completion of thermal cycling and real-time monitoring of cyber green  
163 intercalation, a dissociation step was performed, and the melting curves were  
164 analyzed. Product dissociations with one or two peaks at 80-82 degrees C were  
165 considered positive if the cycle threshold (CT) was less than 45 cycles. Eight  
166 replicate assays were performed, and the final interpretation was considered  
167 positive if at least two replicates produced a specific PCR product based CT and  
168 dissociation analysis.



169

## 170 **Electrocardiogram (ECG)**

171 Standard 12-lead ECG was obtained using an electrocardiograph manufactured by  
172 Tecnologia Eletrônica Brasileira (São Paulo, Brazil)—model TEB ECGPC. All  
173 ECGs were transmitted to an ECG reading center at the Telehealth Center of the  
174 University Hospital of the Federal University of Minas Gerais, for standardized  
175 measurement, reporting and codification according to the Minnesota coding criteria  
176 (MC) in validated ECG data management software [16]. A certified cardiologist  
177 reviewed the exam, and a clinical report was sent back for counseling. All exams  
178 were manually codified according to the Minnesota code as normal or with minor or  
179 major electrocardiographic alterations, as previously described and validated for  
180 Chagas disease [17].

## 181 **Statistical analysis**

182 Ab results were reported as signal-to-cutoff (S/CO) ratios, a function of the  
183 quantity/avidity of *T. cruzi* Ab present in samples. The results from our previous  
184 study in the same Argentinian Chaco region showed bimodal distributions of anti-*T.*  
185 *cruzi* antibodies in blood donors [6]. This bimodality suggests different host-  
186 parasite trajectories in the two groups, potentially reflecting high *versus* low or  
187 absent parasite burden and consequent CD pathogenicity. As such, we aimed to  
188 categorize all four serologic assays into “low” and “high” Ab levels in order to  
189 classify donor participants into two discrete groups based on their Ab reactivity. We  
190 fit mixture models, assuming underlying bimodal normal distributions. We then  
191 selected thresholds for each assay to optimally separate the two distributions using

192 an “expectation minimization” algorithm [18] available at

193 <http://marcchoisy.free.fr/fmm/index.html>.

194 Next, we explored differences in infection characteristics between high- and low-Ab  
195 reactive donor participants. In order to test the hypothesis that individuals with high  
196 Ab levels have higher rates of parasite persistence and parasite loads than those  
197 with low Abs, we compared the proportion with positive *T. cruzi* TC-PCR results at  
198 visit one across these groups.

199 We also compared the change in Ab reactivity between visit 1 and visit 2 according  
200 to baseline Ab category (high versus low) and TC-PCR results. The change in  
201 S/CO values for each serology test was defined as the difference between S/CO at  
202 follow-up and first enrolment visits, with negative values indicating a falling S/CO  
203 value. We analyze both relative and absolute change in S/CO. Relative S/CO  
204 values were defined as: (Follow-up S/CO value – Enrollment S/CO)/Enrollment  
205 S/CO value). A non-parametric significance test for continuous variables quantified  
206 Ab declines.

207 The presence of ECG abnormalities was evaluated as their distributions in three  
208 groups: high Ab levels, low Ab levels, and negative Ab subjects, considering as  
209 negative those individuals non-reactive for all serology tests at enrollment.

210 Analyses were conducted in R statistical software.

211

## 212 **Ethics statement**

213 The study protocol was approved by the local Ethics committee at *Hospital Julio C.*  
214 *Perrando*, located in Resistencia City, the capital of Chaco province. All donor

215 participants provided written informed consent before enrollment and follow-up  
216 visits.

217

## 218 **Results**

### 219 **Cohort characteristics**

220 A total of 455 donors participated in the first visit, with 450 providing valid results  
221 for all serological tests and valid PCR results. In the second visit, 390 of these 450  
222 donors (86%) returned. Of those, 314 had their ECGs performed through the  
223 Telehealth system, allowing their ECG data to be entered and analyzed by the  
224 central reading core. The remaining 76 donors had their ECGs performed locally  
225 and the data could not be used in the study.

226 Table 1 summarizes the epidemiological characteristics of the 450 informative  
227 donors. The majority had significant epidemiological risk exposure: 358 donors  
228 (79.5%) had lived in a house where the vector of *T. cruzi* was present, 370 (82.2%)  
229 had lived in a house with mud walls, and 227 (50.4%) knew that a relative had  
230 suffered from Chagas Disease.

231 **Table 1. Characteristics of 450 enrolled *T. cruzi* seroreactive blood donors,**  
232 **Chaco region, 2018-2019**

Subject characteristics	Full cohort N=450 (%)
Age (years)	
17-25	19 (4.2)

26-35	88 (19.6)
36-45	136 (30.2)
46-55	134 (29.8)
≥ 56	73 (16.2)
Gender	
Male	286 (63.6)
Female	164 (36.4)
Educational level	
No schooling	10 (2.2)
Incomplete primary schooling	138 (30.7)
Complete primary schooling	147 (32.7)
Incomplete secondary schooling	50 (11.1)
Complete secondary schooling	61 (13.5)
Tertiary/University incomplete or complete	44 (9.8)

233

## 234 **Serology testing and PCR detection**


235 Serology analysis of the first visit samples revealed that 289 donors (64%) tested  
236 reactive on all four tests, 36 (8.0%) on three tests, 29 (6.4%) on two tests, and 28  
237 (6.2%) on one test. The remaining 68 samples (15%) were negative on all four  
238 tests, and these were presumed to be false positive results in the initial donation  
239 screening; these 68 donors were excluded from subsequent analyses.

240 Fig 1 presents the distributions of S/CO values for each assay, revealing a clear  
241 bimodal distribution for each assay. Cut-off S/C values could be established to  
242 classify the samples into high and low Ab levels: 9.6 for the Architect Abbott assay,  
243 5.2 for the Vitros assay; 4.8 for Wiener Lysate EIA and 4.7 for Wiener  
244 Recombinant EIA. There were 160 concordant (all four assays) low-level reactive  
245 samples and 179 concordant high-level Ab reactive samples. The remaining 43  
246 samples were discordant with respect to low- and high-level reactivity on the four  
247 assays.

248 **Fig 1. Determination of thresholds of bimodal signal-to-cutoff (S/CO) values**  
249 **distribution for each antibody test**

250 Abbott: CMIA Chagas Architect, Abbott, Germany; EIA Lysate: ELISA Lisado,  
251 Wiener Lab., Argentina; Recomb EIA: ELISA Recombinante, Wiener Lab.,  
252 Argentina; Vitros: Vitros Immunodiagnosics Products Anti-*T. cruzi* (Chagas) Assay  
253 (Ortho Clinical Diagnosis, Raritan NJ, USA. The dotted lines indicate the threshold  
254 values obtained using expectation minimization, assuming normal latent  
255 distributions. They resulted as 9.6 S/CO for CMIA, Architect Abbott; 5.2 S/CO for  
256 Vitros assay; 4.8 S/CO for Lysate EIA and 4.7 S/CO for Recombinant EIA.

257



258


259

260 Fig 2 demonstrates that this classification based on Ab reactivity levels correlates  
261 with the ability to detect parasitemia by TC-PCR. TC-PCR-positive results were  
262 associated with samples with high Ab levels, regardless of the assay used.

263 **Fig 2. Correlation of antibody levels at visit 1 with *T. cruzi* PCR results**

264 Scatter plots of signal-to-cutoff values at visit1.

265 Abbott: CMIA Chagas Architect, Abbott, Germany; EIA Lysate: ELISA Lysado,  
266 Wiener Lab., Argentina; Recomb EIA: ELISA Recombinante, Wiener Lab.,  
267 Argentina; Vitros: Vitros Immunodiagnostics Products Anti-*T. cruzi* (Chagas) Assay  
268 (Ortho Clinical Diagnosis, Raritan NJ, USA).



269

270

271 TC-PCR results were positive on 58-67% of the samples classified as high-level Ab  
272 reactive but only 0-1% of those classified as low-level Ab reactive, depending on  
273 the assays (Table 2). There were only four samples classified as low-level reactive  
274 by at least one of the assays that were PCR positive.

275 **Table 2. *T. cruzi* PCR samples distribution according to classification of high**  
276 **and low antibody levels for each serology test**

Assay	Positive PCR N=127*	Negative PCR N=255*
CMIA		
High n (%)	125 (67)	61 (33)
Low n (%)	2 (1)	194 (99)
VITROS		
High n (%)	127 (67)	63 (33)
Low n (%)	0 (0)	192 (100)
Lysate EIA		
High n (%)	126 (62)	77 (38)
Low n (%)	1 (1)	178 (99)
Recombinant EIA		
High n (%)	126 (58)	90 (42)
Low n (%)	1 (1)	165 (99)

277 \* A total of 382 donors with at least one positive serology result at enrollment and a  
278 valid PCR (two missing)



279 CMIA: Chagas Architect, Abbott; VITROS: VITROS Immunodiagnostics Products  
280 Anti-*T.cruzi* (Chagas) Assay (Ortho Clinical Diagnostics, Raritan NJ; Lysate EIA:  
281 Elisa lisado, Wiener Lab; Recombinant EIA: Elisa Recombinante, Wiener Lab.

282

### 283 **Ab levels on follow up relative to enrollment samples.**

284 The follow-up samples were collected 644 to 1511 days (median 899 days) after  
285 the enrollment samples. The relative decline in Ab reactivity was significantly  
286 higher among low-reactive samples when measured by three of the four kits used:  
287 the recombinant EIA and the two chemiluminescence assays (Fig 3). Measuring  
288 absolute decline was unable to detect differences (Fig 1 supplement).


289

### 290 **Fig 3. The relative decline in antibody levels over time**

291 Box plot graphics show the relative percentage change in S/CO values at follow-up  
292 (visit 2) visit compared to enrollment (visit 1).

293 The change in S/CO values for each serology test was defined as the difference  
294 between S/CO at follow-up and first enrolment visit, such as negative values  
295 indicating a falling S/CO value. For comparisons, 160 and 179 samples were fully  
296 concordant with four low (named as 0) and four high antibodies (named as 4)  
297 results, respectively.

298 The blue dots represent PCR-positive samples, and the pink dots represent PCR-  
299 negative samples.



300

301

## 302 **Ab levels and ECG abnormalities**

303 The presence of ECG abnormalities commonly associated with Chagas

304 cardiomyopathy, such as prolonged QRS complex duration (>120 ms) and Right

305 Bundle Branch Block (RBBB), was low in these asymptomatic donors. We could

306 not establish an association between these abnormalities and Ab levels or PCR  
307 results (Table 3).

308 **Table 3. Electrocardiogram abnormalities distribution in groups of donors**  
309 **with four tests concordant serology reactivity, as high and low antibody**  
310 **levels**

311

<b>Serology results at enrollment</b>	<b>Four high serology tests</b>	<b>Four low serology tests</b>	<b>All negative serology tests</b>
	N(%)	N(%)	N(%)
<b>QRS duration</b>			
> 120 ms	14 (11)	10 (9)	0 (0)
< 120 ms	116 (89)	102 (91)	39 (100)
<b>RBB</b>			
Yes	6 (5)	5 (4)	0 (0)
No	124 (95)	107 (96)	39 (100)
<b>Typical ECG abnormality</b>			
Yes at least one	29 (22)	21 (19)	4 (10)
No	101 (78)	91 (81)	35 (90)

312

313 RBBB: Right Bundle Branch Block

314

## 315 Discussion

316 In this study, we established a prospective cohort of *T. cruzi* seroreactive blood  
317 donors from a highly endemic area in the Chaco region of Argentina. We confirmed  
318 a bimodal distribution of Ab levels and demonstrate for the first time that Ab  
319 reactivity levels correlate with parasite detection in lysed whole blood by a sensitive  
320 TC-PCR assay.

321

322 These findings align with those from our previous cross-sectional study of blood  
323 donors from the same region, in which we described a bimodal distribution of Ab  
324 S/CO values on several *T. cruzi* Ab screening tests; however, *T. cruzi* parasitemia  
325 and longitudinal Ab reactivity patterns were not evaluated in that study [6]. In the  
326 current study, we have demonstrated that the biological process likely underlying  
327 the bimodal distribution is persistence of *T. cruzi* infection based on parasitemia  
328 detected by TC-PCR. Furthermore, we were able to establish a threshold S/CO  
329 value for each of the four assays for classifying cases into high and low Ab level  
330 groups that highly correlated with parasite persistence by PCR and can be used for  
331 counselling and decisions on treatment.

332

333 The association between PCR and Ab levels was initially described in a study we  
334 conducted with blood donor samples from Honduras, the USA, and Brazil [12].  
335 However, due to the pre-screening process of the samples that excluded low  
336 reactive samples in that study, a bimodal distribution of Abs was not demonstrated.

337

338 Despite the relatively short interval between enrolment and follow-up visits in the  
339 current study (median 899 days), Ab decline was observed in the low reactive  
340 group but not in the high reactive group by three of the four assays. This suggests  
341 that individuals in the low Ab group had cleared or were very effectively controlling  
342 parasitemia and replication in tissue reservoirs, reducing the antigenic stimulus,  
343 which lead to Ab waning and eventually complete seroreversion.

344

345 Notably, 93 samples showed discrepant results (reactive to only 1, 2, or 3 assays),  
346 representing approximately 50% of the low reactive samples. Discrepant test  
347 results are common in donor screening and Chagas disease diagnosis, and are  
348 often viewed as due to a lack of sensitivity in the assays. Conversely, our data  
349 suggest that these discrepancies indicate spontaneous cure or effective control of  
350 parasite replication, implying that parallel screening with two immunoassays to  
351 detect discrepant cases may not be necessary.

352 According to PAHO, less than 10% of *T. cruzi* infected individuals receive timely  
353 diagnosis and treatment [19]. Simplifying and optimally eliminating the requirement  
354 for a parallel testing algorithm would improve access to diagnosis in low-income  
355 areas.

356

357 Another important point is that most clinical trials for Chagas disease rely on PCR  
358 results for the initial inclusion criteria of subjects [20]. However, *T. cruzi* PCR is  
359 generally challenging to interpret due to low and intermittent parasitemia, requiring  
360 multiple replicates that often lead to discrepant results. By establishing a cut-off  
361 value using different serological tests, we can improve the screening process for  
362 clinical trials of therapeutics, as the proportion of PCR-positive cases is much  
363 higher among those with elevated Ab levels.

364

365 Ab levels have recently been associated with the development of Chagas  
366 cardiomyopathy [21, 22]. In the present study, we could not establish an  
367 association between disease penetrance and Ab levels, likely due to the young age  
368 of our cohort and short follow-up period following asymptomatic blood donations.

369 In summary, this study provides additional evidence for the bimodal distribution of  
370 Ab reactivity in *T. cruzi*-exposed donors/patients, and the correlation with a  
371 sensitive PCR assay results suggests that spontaneous cure may be responsible  
372 for low reactivity and discordant Ab results. We have also established potential  
373 serological cut-off values that could help classify donors/patients who are more  
374 likely to have persistent parasitemia, which could be used for prognosis and to  
375 indicate the need for treatment.

376

## 377 **References**

- 378 1. Sabino EC, Nunes MCP, Blum J, Molina I, Ribeiro ALP. Cardiac  
379 involvement in Chagas disease and African trypanosomiasis. *Nat Rev*  
380 *Cardiol* [Internet]. 2024 Jul 15; Available from:  
381 <http://dx.doi.org/10.1038/s41569-024-01057-3>
- 382 2. Pérez-Molina JA, Molina I. Chagas disease. *Lancet*. 2018 Jan  
383 6;391(10115):82–94. doi: 10.1016/S0140-6736(17)31612-4.
- 384 3. Crowder LA, Wendel S, Bloch EM, O'Brien SF, Delage G, Sauleda S, et al.  
385 WP-TTID Subgroup on Parasites. International survey of strategies to  
386 mitigate transfusion-transmitted *Trypanosoma cruzi* in non-endemic  
387 countries, 2016-2018. *Vox Sang*. 2022 Jan;117(1):58-63. doi:  
388 10.1111/vox.13164.
- 389 4. Sabino EC, Salles NA, Sarr M, Barreto AM, Oikawa M, Oliveira CD, et al.  
390 Enhanced classification of Chagas serologic results and epidemiologic  
391 characteristics of seropositive donors at three large blood centers in Brazil.  
392 *Transfusion*. 2010 Dec;50(12):2628–37. doi: 10.1111/j.1537-  
393 2995.2010.02756.x.
- 394 5. Salles NA, Sabino EC, Cliquet MG, Eluf-Neto J, Mayer A, Almeida-Neto C,  
395 et al. Risk of exposure to Chagas' disease among seroreactive Brazilian  
396 blood donors. *Transfusion*. 1996 Nov;36(11-12):969–73. doi:  
397 10.1046/j.1537-2995.1996.36111297091740.x.
- 398 6. Remesar M, Sabino EC, Del Pozo A, Mayer A, Busch MP, Custer B.  
399 Bimodal distribution of *Trypanosoma cruzi* antibody levels in blood donors

- 400 from a highly endemic area of Argentina: what is the significance of low-  
401 reactive samples? *Transfusion* . 2015 May 27;55(10):2499–504. doi:  
402 10.1111/trf.13180.
- 403 7. de Sousa AS, Vermeij D, Ramos AN Jr, Luquetti AO. Chagas disease.  
404 *Lancet* [Internet]. 2023 Dec 7; Available from:  
405 [http://dx.doi.org/10.1016/S0140-6736\(23\)01787-7](http://dx.doi.org/10.1016/S0140-6736(23)01787-7)
- 406 8. Pan American Health Organization. Guidelines for the Diagnosis and  
407 Treatment of Chagas Disease. Washington, DC: PAHO; 2019.
- 408 9. Remesar MC, Gamba C, Colaianni IF, Puppo M, Sartor PA, Murphy EL, et  
409 al. Estimation of sensitivity and specificity of several *Trypanosoma cruzi*  
410 antibody assays in blood donors in Argentina. *Transfusion* . 2009  
411 Nov;49(11):2352–8. doi: 10.1111/j.1537-2995.2009.02301.x.
- 412 10. Francolino SS, Antunes AF, Talice R, Rosa R, Selanikio J, de Rezende JM,  
413 et al. New evidence of spontaneous cure in human Chagas' disease. *Rev*  
414 *Soc Bras Med Trop*. 2003 Apr 22;36(1):103–7. doi: 10.1590/s0037-  
415 86822003000100014.
- 416 11. Dias JCP, Dias E, Martins-Filho OA, Vitelli-Avelar D, Correia D, Lages E, et  
417 al. Further evidence of spontaneous cure in human Chagas disease. *Rev*  
418 *Soc Bras Med Trop*. 2008 Sep-Oct;41(5):505–6. doi: 10.1590/s0037-  
419 86822008000500014.
- 420 12. Sabino EC, Lee TH, Montalvo L, Nguyen ML, Leiby DA, Carrick DM, et al.  
421 Antibody levels correlate with detection of *Trypanosoma cruzi* DNA by  
422 sensitive polymerase chain reaction assays in seropositive blood donors  
423 and possible resolution of infection over time. *Transfusion* . 2012 Sep



- 424 25;53(6):1257–65. doi: 10.1111/j.1537-2995.2012.03902.x.
- 425 13. Bertocchi GL, Vigliano CA, Lococo BG, Petti MA, Viotti RJ. Clinical  
426 characteristics and outcome of 107 adult patients with chronic Chagas  
427 disease and parasitological cure criteria. *Trans R Soc Trop Med Hyg.* 2013  
428 Jun;107(6):372–6. doi: 10.1093/trstmh/trt029.
- 429 14. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al.  
430 Long-term cardiac outcomes of treating chronic Chagas disease with  
431 benznidazole versus no treatment: a nonrandomized trial. *Ann Intern Med.*  
432 2006 May 16;144(10):724–34. doi: 10.7326/0003-4819-144-10-200605160-  
433 00006.
- 434 15. Zeledón R, Dias JC, Brilla-Salazar A, de Rezende JM, Vargas LG, Urbina A.  
435 Does a spontaneous cure for Chagas' disease exist? *Rev Soc Bras Med*  
436 *Trop.* 1988 Jan-Mar;21(1):15–20. doi: 10.1590/s0037-  
437 86821988000100003.
- 438 16. Pinto-Filho MM, Paixão GM, Gomes PR, Soares CPM, Singh K, Rossi VA,  
439 et al. Electrocardiographic findings and prognostic values in patients  
440 hospitalised with COVID-19 in the World Heart Federation Global Study.  
441 *Heart.* 2023 Apr 12;109(9):668–73. doi: 10.1136/heartjnl-2022-321754.
- 442 17. Ribeiro ALP, Marcolino MS, Prineas RJ, Lima-Costa MF.  
443 Electrocardiographic abnormalities in elderly Chagas disease patients: 10-  
444 year follow-up of the Bambui Cohort Study of Aging. *J Am Heart Assoc.*  
445 2014 Feb 7;3(1):e000632. doi: 10.1161/JAHA.113.000632.
- 446 18. Trang NV, Choisy M, Nakagomi T, Chinh NTM, Doan YH, Yamashiro T, et  
447 al. Determination of cut-off cycle threshold values in routine RT-PCR assays

- 448 to assist differential diagnosis of norovirus in children hospitalized for acute  
449 gastroenteritis. *Epidemiol Infect.* 2015 Nov;143(15):3292–9. doi:  
450 10.1017/S095026881500059X.
- 451 19. Apr 13. Less than 10% of those infected with Chagas disease receive timely  
452 diagnosis and treatment [Internet]. [cited 2024 Jul 24]. Available from:  
453 [https://www.paho.org/en/news/13-4-2022-less-10-those-infected-chagas-](https://www.paho.org/en/news/13-4-2022-less-10-those-infected-chagas-disease-receive-timely-diagnosis-and-treatment)  
454 [disease-receive-timely-diagnosis-and-treatment](https://www.paho.org/en/news/13-4-2022-less-10-those-infected-chagas-disease-receive-timely-diagnosis-and-treatment)
- 455 20. Bosch-Nicolau P, Fernández ML, Sulleiro E, Villar JC, Perez-Molina JA,  
456 Correa-Oliveira R, et al. Efficacy of three benznidazole dosing strategies for  
457 adults living with chronic Chagas disease (MULTIBENZ): an international,  
458 randomised, double-blind, phase 2b trial. *Lancet Infect Dis.* 2024  
459 Apr;24(4):386–94. doi: 10.1016/S1473-3099(23)00629-1.
- 460 21. Nunes MCP, Buss LF, Silva JLP, Martins LNA, Oliveira CDL, Cardoso CS,  
461 et al. Incidence and Predictors of Progression to Chagas Cardiomyopathy:  
462 Long-Term Follow-Up of *Trypanosoma cruzi*-Seropositive Individuals.  
463 *Circulation.* 2021 Sep 27;144(19):1553–66. doi:  
464 10.1161/CIRCULATIONAHA.121.055112.
- 465 22. Buss LF, Campos de Oliveira-da Silva L, Moreira CHV, Manuli ER, Sales  
466 FC, Morales I, et al. Declining antibody levels to *Trypanosoma cruzi*  
467 correlate with polymerase chain reaction positivity and electrocardiographic  
468 changes in a retrospective cohort of untreated Brazilian blood donors. *PLoS*  
469 *Negl Trop Dis.* 2020 Oct 27;14(10):e0008787. doi:  
470 10.1371/journal.pntd.0008787.

471

## 472 Acknowledgments

473 We acknowledged technical and laboratory personnel at *Centro Especializado en*  
474 *Hemoterapia del Chaco*. We appreciate the administrative personnel for dedicated  
475 work in recruiting blood donors at blood center. We thank the M o H of the Chaco  
476 Province for the relevant support.


477

## 478 Supporting information

### 479 S1 Fig. Absolute changes in antibody levels

#### 480 Figure 1 supplemental

#### 481 Absolute changes in antibody levels



482